ArticleEuropean journal of medical research2026
Impact of dexamethasone treatment on hematological indicators in patients with fat embolism syndrome.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFat embolism syndrome (FES) is a serious complication of orthopedic trauma characterized by hypoxemia, hematologic abnormalities, and systemic inflammation. The dynamic interaction between triglycerides (TG), free fatty acid-mediated endothelial injury, and cytokine amplification has not been fully characterized in clinical cohorts. This study evaluated whether dexamethasone (DXM) modifies hematologic and inflammatory trajectories in FES and explored these findings within a proposed lipid pathological resonance (LPR) framework.
methodsThis retrospective cohort study included 134 adults diagnosed with FES between June 2020 and June 2024. Patients received either DXM (10 mg/day for five days) or standard care. Daily TG, interleukin-6 (IL-6), red blood cell (RBC) counts, and platelet (PLT) counts were recorded for five days. Longitudinal trends were analyzed using generalized estimating equations (GEE), adjusting for transfusion volume and injury variables. Subgroup analyses compared survivors and non-survivors.
resultsBaseline characteristics were comparable. Beginning on day 3, the DXM group exhibited faster declines in TG and IL-6 and earlier improvements in RBC and PLT. Significant group × time interactions were observed for TG (P < 0.01), IL-6 (P < 0.001), RBC (P < 0.05), and PLT (P < 0.01). DXM-treated patients required fewer transfusions (P < 0.001). Non-survivors showed persistent TG-IL-6 elevation and minimal hematologic recovery, consistent with failure to interrupt the lipid-cytokine amplification cycle proposed in the LPR model.
conclusionDXM was associated with improved inflammatory and hematologic trajectories in FES. These findings support the existence of a TG-driven cytokine amplification mechanism contributing to disease progression and suggest that DXM may attenuate this resonance loop. Prospective trials incorporating mechanistic biomarkers are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.